Ipatasertib
Pan-AKT inhibitor / Ipatasertib is a selective (against a panel of 230 kinases) and potent pan-Akt inhibitor (IC50s: Akt1 = 5 nM, Akt2 = 18 nM, Akt3 = 8 nM).1 It displayed efficacy in xenograft models of prostate, breast, ovarian, colorectal, non-small cell lung, glioblastoma, and melanoma cancers.2 In clinical trials.
Biochemicals & reagents
1001264-89-6
GDC-0068; RG7440
1) Blake et al. (2012), Discovery and preclinical pharmacology of a selective ATP-competitive Akt inhibitor (GDC-0068) for the treatment of human tumors; J. Med. Chem. 55 8110 2) Lin et al. (2013), Targeting Activated Akt with GDC-0068, a Novel Selective Aky Inhibitor That is Efficacious in Multiple Tumor Models; Clin. Cancer Res. 19 1760
-20°C
TARGET: Kinase -- PATHWAY: AKT; Cell cycle; NFkappaB; Apoptosis inducer -- RESEARCH AREA: Cell death -- DISEASE AREA: Cancer